# Junta clínica — PT-pseudo_b9f0b7018502 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b9f0b7018502",
  "pid": "PT-pseudo_b9f0b7018502",
  "task": 1,
  "psa": 8.7,
  "age": 54,
  "months": 1,
  "pirads": "5",
  "psad": 0.4,
  "psav": 1.21,
  "psap": 7.0,
  "vol": 23.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8609265,
  "medhx": "Coronary artery disease",
  "meds": "atorvastatin, metoprolol",
  "notes": "PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.",
  "pmhx": [
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "182 cm",
    "bmi": "27.2",
    "bp": "97/85 mmHg",
    "hr": "82 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "30 Jan 2025",
  "enc_ref": "Dr. L. Smits (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy."
    },
    {
      "s": "History",
      "t": "An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Never married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Orthopaedic outpatient — knee follow-up"
  ],
  "alcohol": "5 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9f0b7018502
Task: 1

Encounter: Urology - outpatient on 30 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 8.7 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: 1.21 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 23.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8609265 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease
  - Problem list / PMHx: Coronary artery disease
  - Current medication: atorvastatin, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.

Vitals: weight 90 kg, height 182 cm, BMI 27.2, BP 97/85 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy.

History: An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact.

Physical examination: DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses.

Patient info: graphic designer; Never married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 5 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.73
  uncertainty  +/- 0.11 epistemic (95% band 0.50-0.95); among patients I cannot tell apart the outcome was 0.84 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 1 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 54 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 8.7 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 23 mL (1% of my signal; from log_vol, vol) · PSA density = 0.4 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.86 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 54 · DRE = Normal · PSA = 8.7 ng/mL · prostate volume = 23 mL · PSA density = 0.4 · PI-RADS = 5 · comorbidity = 1 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 48 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.29: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  2. distance 1.69: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  3. distance 1.81: PI-RADS 5, PSA 13.5, PSAD 0.452, age 66, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 lesion in a man in active surveillance."

PRECEDENT: BIOPSY (weighted vote 0.60 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · age = 54 · PSA = 8.7 ng/mL · PSA density = 0.4 · PI-RADS = 5
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 23 mL · csPCa probability = 0.86 · comorbidity = 1 on the problem list
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   PI-RADS = 5
  important  prior biopsy = Positive · age = 54 · PSA = 8.7 ng/mL
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 23 mL · PSA density = 0.4 · comorbidity = 1 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guidelines discuss using PI-RADS scores and PSA density in relation to biopsy decisions. "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy." This suggests that the PI-RADS score and PSA density are relevant in guiding the decision.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline makes the PI-RADS score and PSA density decisive, whereas EXPERT-STRUCTURED marked the prior biopsy as decisive. The guideline suggests that the PI-RADS score and PSA density are relevant in guiding the decision, which is different from the expert's focus on the prior biopsy status. The guideline requires that the panel variable that the guideline treats as context, the prior biopsy status, is weighed against the guideline's guidance, which suggests that the guideline requires the documented grade of the prior biopsy to be considered. The guideline needs the prior grade of the prior biopsy to be established to determine the next step.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: a rising PSA velocity is a factor that should be considered in the decision.
laboratory_results - the PSA density: the PSA density is a factor that should be considered in the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the documented grade of the prior biopsy, as the cohort expert noted that the panel alone is insufficient.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, extraprostatic extension, and comparison to an earlier study inform the decision?
  psa_trend (get_psa_trend) -> Does the PSA velocity inform the decision?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy (Gleason or ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> Does the PSA density inform the decision?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?
  Q2. Does the PSA velocity support a decision to biopsy?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report: Maastricht UMC+ | Department of Radiology | 28 January 2025. The lesion size and zone is described as "spanning roughly 12 mm" in the left posterior peripheral zone, with "early, focal, and vigorous enhancement." Comparison is "new" as it is the current assessment.
psa_trend: The PSA velocity is noted as rising, with values from "3.1 (Jun 2022)" to "8.7 (Jan 2025)," indicating a significant rise over time.
previous_notes: The documented grade of the prior biopsy is "Gleason 3+5," the number of biopsy sessions is not explicitly stated beyond "a subsequent targeted biopsy," and he is not explicitly stated to be on a surveillance protocol with a confirmatory biopsy due.
laboratory_results: The PSA density is reported as "0.4 ng/mL/mL," which is a factor to consider per the EAU guideline.

WHAT I DID NOT OPEN
family-history anamnesis, as it was not explicitly requested by the moderator and is not critical to the immediate decision based on the other opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- The PI-RADS score of 5 from the mpMRI suggests a high likelihood of clinically significant prostate cancer.
- The rising PSA velocity from the PSA trend suggests ongoing disease progression.
AGAINST sampling this patient now:
- The previous notes indicate a prior biopsy result of Gleason 3+5, which is a known grade, and the current status is monitoring.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 8.70 ng/mL over 5 points spanning 31 months; velocity +2.13 ng/mL per year; doubling time about 21 months.
PROJECTION at 6 months: 11.6 ng/mL, conformal 95% band 3.3-40.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 8.7 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.77
  uncertainty  +/- 0.12 epistemic (95% band 0.53-1.00), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Normal (5% of my signal; from dre_suspicious) · PSA = 8.7 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 23 mL (4% of my signal; from log_vol, vol) · PSA density = 0.4 (0% of my signal; from psad_calc) · comorbidity = 1 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.73  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.77  ('firm' tier, fusion_full; weight 4.5)
  EXPERT-EXPERIENCE  BIOPSY, p(biopsy)=0.60  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: GG 4 ("Gleason 3+5")

RULE THAT FIRED: documented prior grade GG 4 (Gleason 3+5) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-EXPERIENCE. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          54                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psa          8.7 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          23 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.4                          E1:not E3:not cohort:not library:IMP E2:—            -> noted
  cspca        0.86                         E1:not E3:— cohort:— library:not E2:—                -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> decisive
  comorbidity  1 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened appear to answer the moderator's questions. The `previous_notes` state the prior biopsy grade is "Gleason 3+5," and the `psa_trend` indicates a rising PSA velocity.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY. The protocol states that a documented prior grade of GG 4 (Gleason 3+5) is the rule that fired, leading to the decision of NO BIOPSY.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? Answered by the `previous_notes`: "Gleason 3+5".
Q2. Does the PSA velocity support a decision to biopsy? Answered by the `psa_trend`: The velocity is rising, which supports the leaning towards biopsy, but the panel protocol overrides this based on the prior grade.

WHAT CARRIES WEIGHT, AND WHY
documented prior grade: decisive: noted: Gleason 3+5 (justifies PANEL answer). I agree with the PANEL's decision based on this finding. PSA velocity: important: noted: rising (justifies leaning towards biopsy, but overridden). I would move the weight of PSA velocity to 'important' as it reflects current disease behavior. My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
I suggest adhering to the PANEL-PROTOCOL's decision of NO BIOPSY, as the documented prior grade of Gleason 3+5 is the decisive factor according to the protocol.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

54y male, PSA 8.7, PI-RADS 5, prior biopsy Gleason 3+5. The documented prior grade of Gleason 3+5 dictates management without repeat biopsy. The PI-RADS 5 finding is consistent with known high-grade disease, and the prior tissue diagnosis is sufficient for treatment planning. No earlier MRI to compare with.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
